Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.

Autor: Harris DM; Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA. harris.dana@mayo.edu., Stancampiano FF; Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA., Burton MC; Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, USA., Moyer AM; Department of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA., Schuh MJ; Department of Pharmacy, Mayo Clinic, Jacksonville, FL, USA., Valery JR; Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA., Bi Y; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Jazyk: angličtina
Zdroj: Digestive diseases and sciences [Dig Dis Sci] 2021 Dec; Vol. 66 (12), pp. 4120-4127. Date of Electronic Publication: 2021 Jan 21.
DOI: 10.1007/s10620-020-06814-1
Abstrakt: Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.
(© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: